Evaluation of different transposon-based genetic modification tools for CAR-T cell therapy

Abdo, Luiza de Macedo; Aragão, Emmanuel; Hajdu, Karina; Mannarino, Eduardo; Andrade, Clara; Ribeiro, Leonardo; Bonamino, Martín.
No convencional en Portugués | ARCA | ID: arc-58016

Documentos relacionados

  1. The "Great Debate" at Immunotherapy Bridge 2020, December 3rd, 2020.
  2. The Role of Systemic Filtrating Organs in Aging and Their Potential in Rejuvenation Strategies.
  3. Metabolic Frugality Marks Cancer Cells for Immune Targeting.
  4. Pre-encoded responsiveness to type I interferon in the peripheral immune system defines outcome of PD1 blockade therapy.
  5. Modular pooled discovery of synthetic knockin sequences to program durable cell therapies.
  6. Nanomaterials in tumor immunotherapy: new strategies and challenges.
  7. CD19 occupancy with tafasitamab increases therapeutic index of CART19 cell therapy and diminishes severity of CRS.
  8. Targeting RNA N6-methyladenosine to synergize with immune checkpoint therapy.
  9. Therapeutic synthetic and natural materials for immunoengineering.
  10. [Combination of Immunotherapy and Hyperthermia].